Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

News SummaryMost relevantAll newsSector newsTweets

Catalyst Pharmaceutical Partners, Inc. : Catalyst Receives Guidance From NASDAQ Regarding Minimum Bid Price Requirement

share with twitter share with LinkedIn share with facebook
share via e-mail
12/27/2012 | 03:05pm CET

CORAL GABLES, Fla., Dec. 27, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it received a Nasdaq Staff Deficiency Letter, dated December 24, 2012, indicating that the Company is not in compliance with the Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

The Nasdaq Listing Rules (the "Rules") require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets this requirement. In light of the deficiency, the Rules also provide the Company with a grace period of 180 calendar days in which to regain compliance. If at any time during this grace period the bid price of the Company's security closes at or above $1.00 per share for a minimum of ten consecutive business days, the Nasdaq Stock Market will provide the Company with a written confirmation of compliance and the matter will be closed.

In the event the Company does not regain compliance with the Rule prior to the expiration of the grace period, the Company may be eligible for an additional 180-day grace period if at such time it meets the initial listing standards for listing on the Nasdaq Capital Market, with the exception of the bid price requirement.

The Company understands the Nasdaq requirements and believes it will be able to regain compliance with the Rules within the allotted grace period.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting orphan drug diseases and disorders of the central nervous system. Catalyst has three products in development, Firdapse™, which Catalyst plans to develop for commercialization in North America as a treatment for Lambert-Eaton Myasthenic Syndrome (LEMS), CPP-115, a GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin, which Catalyst plans to develop for the treatment of epilepsy (primarily infantile spasms) and CPP-109 (vigabatrin), which Catalyst hopes to develop for the treatment of Tourette's Disorder. For additional information about Catalyst, please visit www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether the Company will be able to regain compliance with the Rules within any applicable grace periods, whether any of the Company's product candidates will ever be approved for commercialization, and those factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany

         Catalyst Pharmaceutical Partners

         Chief Executive Officer

         (305) 529-2522

         [email protected]

         Melody Carey

         Rx Communications Group


         (917) 322-2571

         [email protected]
Source: Catalyst Pharmaceutical Partners, Inc.

News Provided by Acquire Media

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
01/08 CATALYST PHARMACEUTICALS, INC. : Other Events (form 8-K)
2017 CATALYST PHARMACEUTICALS : Announces Closing of Previously Announced Public Offe..
2017 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Financial Statements a..
2017 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
2017 Catalyst Pharmaceuticals, Inc. Announces Closing of Previously Announced Publ..
2017 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Entry into a Material ..
2017 CATALYST PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Fin..
2017 CATALYST PHARMACEUTICALS, INC. : Prices Previously Announced Public Offering of ..
2017 CATALYST PHARMACEUTICALS : Announces Positive Top Line Results from Second Phase..
2017 REGENERON PHARMACEUTICALS, INC. (NAS : REGN) And Catalyst Pharmaceuticals, Inc. ..
More news
News from SeekingAlpha
2017 YOUR DAILY PHARMA SCOOP : Biogen Setback, Ironwood Commences Trial, Vtv Signs 2 ..
2017 YOUR DAILY PHARMA SCOOP : Aclaris Gets Approval, Egalet Surges, Alnylam Gains As..
2017 YOUR DAILY PHARMA SCOOP : Conatus Looks Undervalued, Teva Announces Restructurin..
2017 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
Financials ($)
Sales 2017 -
EBIT 2017 -18,8 M
Net income 2017 -18,7 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 0
Capi. / Sales 2018 45,7x
Capitalization 328 M
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Technical analysis trends CATALYST PHARMACEUTICALS I
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,19 $
Spread / Average Target 62%
EPS Revisions
Patrick J. McEnany Chairman, President & Chief Executive Officer
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer & Head-Regulatory Affairs
Philip H. Coelho Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES10.30%104 801
GENMAB11.42%11 532
EXELIXIS, INC.-0.07%8 772